BPC-157 (5 mg Vial) Dosage Protocol
Complete BPC-157 dosage protocol for the 5 mg vial. Includes injection dosing schedule and healing peptide research cycle info.
Dosage Schedule
| Period | Dose |
|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) |
| Weeks 3–4 | 400 mcg (0.4 mg) |
| Weeks 5–8+ | 600 mcg (0.6 mg) |
Route: Subcutaneous · Frequency: Once daily · Cycle: 8–12 weeks
How It Works
BPC-157 is a synthetic peptide corresponding to a partial sequence of human gastric juice protein. Preclinical studies suggest it modulates nitric oxide pathways and growth-factor expression to promote angiogenesis and collagen deposition in damaged tissues. Animal models report accelerated healing of gut, tendon, ligament, and muscle injuries.
Potential Benefits
- •Supports tissue repair in gut, tendon, muscle, and skin injury models (animal data).
- •Demonstrates anti-inflammatory and cytoprotective properties in preclinical settings.
- •Phase I safety studies report good tolerability with no serious adverse events at tested doses.
- •Long-term human safety and efficacy remain under investigation.
Side Effects & Risks
- •Occasional mild injection-site reactions (redness, itch).
- •Human clinical data remain limited to early-phase safety trials.
Important Notes
- Use new sterile insulin syringes for each injection; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- BPC-157 human data are preliminary; clinical decisions should involve qualified healthcare providers.
Storage Instructions
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions.
- Once mixed: Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation.
References
- [1]Klicek R et al. BPC-157 promotes colocutaneous fistula healing via NO-system modulation. J Pharmacol Sci.View Source
- [2]Józwiak M et al. Multifunctionality and possible medical application of BPC-157. Pharmaceuticals (MDPI) 2025.View Source
- [3]Sikiric P et al. BPC-157 stable gastric pentadecapeptide: novel therapy for wound healing. Curr Pharm Des.View Source
- [4]NCT02637284: PCO-02 Phase I safety and PK trial of oral BPC-157. ClinicalTrials.gov.View Source
Research & Educational Use Only: This protocol is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any decisions related to peptides or any other compounds.